Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients' First Degree Relatives

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2010 by Tel-Aviv Sourasky Medical Center.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Tel-Aviv Sourasky Medical Center
ClinicalTrials.gov Identifier:
NCT01089270
First received: March 17, 2010
Last updated: NA
Last verified: March 2010
History: No changes posted

March 17, 2010
March 17, 2010
March 2010
March 2011   (final data collection date for primary outcome measure)
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients' First Degree Relatives
Not Provided

Parkinson Disease is one of the most common neurodegenerative illnesses. First degree relatives of Parkinson patient are in high risk for developing the disease. We will try to detect early changes in brain metabolism before the appearance of Parkinson symptoms.

Participants: first degree relatives of diagnosed Parkinson patients that carry a gene mutation in either LRRK2 or GBA genes.

The examination results will be given to the participants by a doctor from the neurology department.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

First degree relatives of diagnosed Parkinson patients that carry either LRRK2 or GBA gene mutation.

Ages: 30-80

Parkinson Disease
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
80
Not Provided
March 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • healthy first degree relatives of diagnosed Parkinson patients

Exclusion Criteria:

  • patients unable to understand and sign an informed consent
  • minors
  • people with psychiatric disorders or a history of major head trauma
Both
30 Years to 80 Years
Yes
Contact: Einat Even-sapir, PhD, MD 972-3-6974444 ext 3536 evensap@tasmc.health.gov.il
Contact: Ayelet Kurzband, BA 972-3-6974444 ext 3536 ayeletk@tasmc.health.gov.il
Israel
 
NCT01089270
TASMC-10-EES-0519-CTIL
Yes
Einat Even-Sapir MD, PhD. Head, Dept of Nuclear Medicine, Tel Aviv Sourasky Medical Center
Tel-Aviv Sourasky Medical Center
Not Provided
Principal Investigator: Einat Even-Sapir, MD, PhD Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Tel-Aviv Sourasky Medical Center
March 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP